The global dendritic cell cancer vaccine market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factors that are expected to boost the market include an increase in the prevalence of cancer, improvement of technology such as drug innovations regarding cancer, an upsurge in awareness about cancer and their available therapies in the market. Dendritic cells (DCs) are one of the major antigen-presenting cells found in lymphoid organs. They have prompted their recent application to therapeutic cancer vaccinations as they are uniquely effective in their ability to present antigens to T cells. The main function of the dendritic cells is antigen display and activation of T-cells. Antigen display presents the identity of the pathogen to T-cells for their identification and elimination from the body. They are rare kinds of leukocytes. Isolated dendritic cells (DCs) loaded with tumor antigen ex vivo and administered as a cellular vaccine are found to induce protective and therapeutic anti-tumor immunity in experimental animals. 

Some other factors that are expected to fuel the market growth include the rise in investments in R&D activities, together with positive results in clinical trials, which are anticipated to drive the growth of the market. Other factors that are boosting the growth of the market include the ability of dendritic cells to target multiple cancer antigen capability, a rise in the geriatric population, and technological advancements. Currently, the three marketed cancer vaccines commercially available in different geographies include Provenge (U.S.), CreaVax-RCC (South Korea), and Tumor Antigen Presenting Cells, such as TAPCells (Chile). Provenge is the first marketed dendritic cell vaccine available in the market. They are targeted to treat prostate cancer, metastatic renal cell carcinoma, melanoma, and prostate cancer. 

Market Coverage

    • The market number available for – 2020-2027

    • Base year- 2020

    • Forecast period- 2021-2027

    • Segment Covered- 

o By Product Type 

o By End-Users

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape: Argos Therapeutics, and Dendreon Corp., among others

Key questions addressed by the report

    • What is the market growth rate?

    • Which segment and region dominate the market in the base year?

    • Which segment and region will project the fastest growth in the market?

    • How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

    • Who is the leader in the market?

    • How are players addressing challenges to sustain growth?

    • Where is the investment opportunity?

Global Dendritic Cell Cancer Vaccine Market Report by Segment

By Product Type

    • CreaVax

    • Sipuleucel-T (Provenge)

    • Others

By End-Users

    • Adults

    • Pediatrics

Global Dendritic Cell Cancer Vaccine Market Report by Region

North America       

    • US

    • Canada

Europe

    • Germany

    • UK

    • France

    • Spain

    • Italy

    • Rest of Europe

Asia-Pacific    

    • China

    • Japan

    • India

    • Rest of Asia-Pacific

Rest of the World

    • Latin America

    • Middle East and Africa